Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

August 31, 1999

Primary Completion Date

December 31, 2006

Study Completion Date

September 30, 2013

Conditions
Lymphoma
Interventions
DRUG

Rituximab

375 mg/m\^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.

DRUG

GM-CSF

250 mcg subcutaneously 3 times a week for 8 weeks.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT01939730 - Rituximab + GM-CSF in Patients With Follicular B-Cell Lymphoma | Biotech Hunter | Biotech Hunter